ReviewClinical reviews in allergy & immunology2013
Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.
Review in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- The Association of Serum Immunoglobulins with Risk of Cardiovascular Disease and Mortality: the Rotterdam Study.Journal of clinical immunology · 2023Article
- Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease.Frontiers in pharmacology · 2020Article
- Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension.PloS one · 2019Article
- Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions.JCI insight · 2018Article
- Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?Hepatology international · 2018Article
- Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.Laboratory investigation; a journal of technical methods and pathology · 2016Review
- Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus.Clinical and experimental immunology · 2015Article
- Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.Antioxidants & redox signaling · 2015Review
- Liquid biopsies in patients with diffuse glioma.Acta neuropathologica · 2015Article
- Article
- Autoimmunity in 2013.Clinical reviews in allergy & immunology · 2014Review
- Unique topics and issues in rheumatology and clinical immunology.Clinical reviews in allergy & immunology · 2014Article
- Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.World journal of cardiology · 2014Review
- The autoimmune side of heart and lung diseases.Clinical reviews in allergy & immunology · 2013Review
- Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals.Mediators of inflammation · 2012Article
- Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last 15 years, a growing body of evidence supported the fact that auto-antibodies represent not only emergent markers but also active mediators of cardiovascular disease (CVD), clinically represented mostly by acute coronary syndrome (ACS) and stroke. There is a contrasted relationship between auto-antibodies and CVD, some being protective, while others acting as potential risk factors. Therefore, we performed a review of the literature on the respective cardiovascular prognostic value of the most relevant auto-antibodies in ACS and stroke, and their putative pathophysiological properties in atherogenesis. This review highlights auto-antibodies as active modulators of the innate immune system in atherogenesis (either toward a pro- or anti-inflammatory response), or by affecting basal heart rate regulation (anti-apoA-1 IgG). Given their apparent prognostic independency towards traditional cardiovascular risk factors, the data available in the literature indicates that some of those auto-antibodies could be of valuable help for cardiovascular risk stratification in the future, especially because their deleterious effects have been shown to be potentially abrogated in vivo and in vitro by existing therapeutic modalities. Although evidence in humans is currently lacking, these studies may open innovative therapeutic perspectives for CVD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.